PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(12 sites)
China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Peking University Third Hospital, Beijing Sichuan Cancer Hospital, Chengdu Fujian Province Cancer Hospital, Fuzhou Guizhou Cancer Hospital, Guiyang Zhejiang Cancer Hospital, Hangzhou Jiangxi Cancer Hospital, Nanchang The First Affiliated Hospital of Guangxi Medical University, Nanning Fudan University Shanghai Cancer Center, Shanghai Zhongnan Hospital of Wuhan University, Wuhan The First Affiliated Hospital of Xiamen University, Xiamen Last updated January 2025